EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

UniPharma Co., Ltd. (6621) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of UniPharma Co., Ltd. TWD 3.86, price TWD 11.95, upside -67.7%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0006621006

UC Thin data Sep 24, 2026

UniPharma Co., Ltd.

6621 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 3.86 TWD · Strongly overvalued (−68%)
!Quality 48/100
!Weak Growth (revenue 5y −8.6 %/yr)
!Loss-making · -45.8% net margin (TTM)
!negative free cash flow
!Trails peers (2/9)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch UniPharma Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

15.20 TWD 10.65 TWD Fair Value 3.86 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range 10.65 TWD – 15.20 TWD · fair‑value band 2.55 TWD – 4.83 TWD · the 11.95 TWD price screens above the 3.86 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.

Follow UniPharma Co. in your weekly email

Every Wednesday you see whether UniPharma Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology.

Show more

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was founded in 1998 and is based in Taipei, Taiwan.

Stock analysis

UniPharma Co., Ltd. (6621) currently trades at 11.95 TWD, while our model-based Fair Value estimate is 3.86 TWD, implying the stock looks roughly 209.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2.55 TWD (bear) to 4.83 TWD (bull), the price of 11.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

UniPharma Co., Ltd. reported revenue of 88.4M TWD in FY2025 versus 105M TWD in FY2021, a compound −4.3%/yr. Reported net income was −40.5M TWD in FY2025.

Key figures

Market cap 424M TWD (≈ $13.3M) · P/S ratio 4.58 · EPS (TTM) −1.14 TWD · Net margin −45.8% · Return on equity −15.8% · Return on assets (EBIT) −10.2% · Operating margin −47.4% · Revenue (TTM) 88.4M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −68%, 6621 screens richer than that median.

Fair Value models

Bear 2.55 TWD Fair Value 3.86 TWD Bull 4.83 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 3.19 TWD 4.27 TWD 6.38 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 3.19 TWD 4.27 TWD 6.38 TWD 51

Open the full fair value analysis →

Notify me when 6621 reaches fair value

Put 6621 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 48/100

Of which business quality 47 · Market factors (momentum, volatility) 48

Profitability 9
Margins and returns on capital today
Quality Growth 31
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 32
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.9% (2020) → −49.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6621 screens 210% overvalued. Compare with Merck KGaA →

Compare UniPharma Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −68% · Bottom 25%
Profitability
Return on assets −9% · Bottom 25%
Net margin (TTM) −46% · Bottom 25%
Operating margin (TTM) −47% · Bottom 25%
Growth and dividend
Revenue growth −5% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.06× · Cheapest 25%
P/S (TTM) 0.15× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

UniPharma Co., Ltd. · Fair Value
3.86 TWD −210%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "UniPharma Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6621

Frequently asked questions

Is UniPharma Co., Ltd. (6621) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3.86 TWD versus a price of 11.95 TWD, about −68% upside (overvalued).
What is the fair value of 6621?
Our model-based fair value for UniPharma Co., Ltd. is 3.86 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 11.95 TWD.
What is the quality score of 6621?
UniPharma Co., Ltd. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UniPharma Co., Ltd. (6621)?
Our model-based price target is the fair value of 3.86 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2.55 TWD, optimistic scenario 4.83 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the UniPharma Co., Ltd. stock forecast for 2026?
Our models put fair value at 3.86 TWD, about −68% upside versus a price of 11.95 TWD (overvalued). Cautious scenario 2.55 TWD, optimistic scenario 4.83 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of UniPharma Co., Ltd. (6621)?
UniPharma Co., Ltd. reported trailing-twelve-month revenue of about 88.4M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of UniPharma Co., Ltd. (6621)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UniPharma Co., Ltd. it is 3.86 TWD per share (as of Sep 24, 2026), against a price of 11.95 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is UniPharma Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6621 trades above its calculated fair value: price 11.95 TWD, fair value 3.86 TWD, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6621?
No. The price is what the market pays today (11.95 TWD); the fair value is what the company's own numbers justify (3.86 TWD). For UniPharma Co., Ltd. the two are 8.09 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is UniPharma Co., Ltd. worth?
The market values UniPharma Co., Ltd. at about 424M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 11.95 TWD; our models calculate a fair value of 3.86 TWD per share.
What do the bullish and bearish scenarios say about 6621?
Our models span a range for UniPharma Co., Ltd.: cautious scenario 2.55 TWD, base 3.86 TWD, optimistic 4.83 TWD per share (as of Sep 24, 2026, price 11.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of UniPharma Co., Ltd. (6621)?
Balance-sheet figures for UniPharma Co., Ltd. (as of Sep 24, 2026): return on equity −15.8%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
Which stocks are comparable to UniPharma Co., Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UniPharma Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 11.95 TWD, calculated fair value 3.86 TWD (−68%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6621 calculated?
We run UniPharma Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.86 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. UniPharma Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UniPharma Co., Ltd. (6621)?
The closing price on Sep 23, 2026 was 11.95 TWD. Our model-based fair value is 3.86 TWD, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UniPharma Co., Ltd. right now?
The price sits above even our optimistic bull case (4.83 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (2.55 TWD to 4.83 TWD) leaves room in how you read the outcome.

Key figures of UniPharma Co., Ltd.

How large is the market capitalisation of UniPharma Co., Ltd. (6621)?
The market capitalisation of UniPharma Co., Ltd. is 424M TWD (≈ $13.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UniPharma Co., Ltd. (6621)?
The price-to-sales ratio of UniPharma Co., Ltd. is 4.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of UniPharma Co., Ltd. (6621)?
Earnings per share at UniPharma Co., Ltd. are −1.14 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of UniPharma Co., Ltd. (6621)?
The net margin of UniPharma Co., Ltd. is −45.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UniPharma Co., Ltd. (6621)?
The return on equity (ROE) of UniPharma Co., Ltd. is −15.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UniPharma Co., Ltd. (6621)?
On an EBIT basis the return on assets of UniPharma Co., Ltd. is −10.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UniPharma Co., Ltd. (6621)?
The operating margin of UniPharma Co., Ltd. is −47.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UniPharma Co., Ltd. (6621)?
Revenue at UniPharma Co., Ltd. is growing −5.0% versus a year earlier (3y avg −11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does UniPharma Co., Ltd. (6621) generate?
The free cash flow of UniPharma Co., Ltd. is −38.6M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does UniPharma Co., Ltd. (6621) hold?
UniPharma Co., Ltd. holds more cash than debt, 43.9M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch UniPharma Co., Ltd. in the live analysis

One click puts UniPharma Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.